

Golden State Medical Supply – Recall of enalapril tablets

- On March 16, 2022, [Golden State Medical supply announced](#) a consumer-level recall of several lots of [enalapril](#) tablets due to a confirmed out-of-specification result for unknown impurity found in one lot.
- The following products started shipping October 30, 2019.

Product Description	NDC#	Lot # (Expiration Date)
Enalapril 2.5 mg tablets	60429-183-90	GS031715 (10/2022); GS035315 (4/2023); GS040149 (11/2023); GS039200 (11/2023); GS039199 (4/2023); GS038038 (4/2023); GS036905 (4/2023); GS035945 (4/2023); GS033191 (10/2022); GS031436 (10/2022); GS029974 (10/2022); GS029973 (10/2022); GS028301 (6/2022); GS034212 (12/2022); GS033940 (10/2022)
Enalapril 5 mg tablets	60429-184-90	GS034490 (2/2023); GS035197 (2/2023); GS029041 (9/2022); GS029353 (9/2022); GS029861 (9/2022); GS030056 (10/2022); GS030869 (10/2022); GS040151 (12/2023); GS033943 (10/2022); GS041654 (3/2024); GS040708 (12/2023); GS040150 (10/2023); GS039559 (10/2023); GS038763 (10/2023); GS038089 (10/2023); GS037400 (6/2023); GS036759 (6/2023); GS035947 (6/2023); GS035596 (6/2023); GS035198 (3/2023); GS041107 (12/2023)
Enalapril 10 mg tablets	60429-185-90	GS036194 (6/2023); GS027890 (4/2022); GS041656 (5/2024); GS041655 (1/2024); GS041109 (12/2023);

		GS041108 (9/2023); GS039840 (12/2023); GS039412 (12/2023); GS038729 (9/2023); GS038728 (8/2023); GS038177 (8/2023); GS037526 (8/2023); GS036760 (8/2023); GS035598 (5/2023); GS035240 (5/2023); GS030057 (10/2022); GS028177 (4/2022); GS028488 (4/2022); GS028847 (9/2022); GS028848 (9/2022); GS036981 (8/2023); GS029862 (10/2022); GS034810 (1/2023); GS030481 (10/2022); GS030870 (10/2022); GS031060 (10/2022); GS031437 (10/2022); GS031438 (10/2022); GS033527 (10/2022); GS034231 (10/2022); GS029627 (10/2022)
Enalapril 20 mg tablets	60429-186-90	GS035031 (3/2022); GS039560 (11/2022); GS038359 (11/2022); GS037986 (11/2022); GS037401 (9/2022); GS036904 (5/2022); GS035199 (3/2022); GS041110 (12/2022); GS036495 (5/2022)

- Enalapril tablets are indicated for the treatment of hypertension, treatment of symptomatic congestive heart failure, and in stable asymptomatic patients with left ventricular dysfunction to decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Patients should contact their physician or health care provider if they have experienced any problems that may be related to taking or using the recalled enalapril tablets.
- Contact Golden State Medical Supply by phone at **1-800-284-8633** or by email at recalls@gsms.us for more information about the recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.